D019233ProceduresE02.887701070.968755Retreatmentplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson32805058Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes MBritish journal of haematologyImpact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.Br J Haematol2020-08-17T00:00:002020Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.33411569Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Dalag L, Han R, Ahmed OThe British journal of radiologySafety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.Br J Radiol2021-01-07T00:00:002021Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory.Medicine-Hematology and Oncology33602684Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani ASClinical cancer research : an official journal of the American Association for Cancer ResearchInotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.Clin Cancer Res2021-02-18T00:00:002021Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.AnandPatelAnand Patel41.7886000000000087.598699999999994043Patel, Anand0000-0002-0296-8686Assistant Professor34182115Barry IP, Barns M, Verhoeven E, Wong J, Dubenec S, Heyligers JM, Milner R, Shutze WP, Bachoo P, Vlaskovky P, Mwipatayi BP, GREAT participantsAnnals of vascular surgeryExcluder Stent Graft-Related Outcomes in Patients with Aortic Neck Anatomy Outside of Instructions For Use (IFU) within the Global Registry for Endovascular Aortic Treatment (GREAT): Mid-term Follow-Up Results. Ann Vasc Surg. 2021 Oct; 76:222-231.Ann Vasc Surg2021-06-25T00:00:002021Excluder Stent Graft-Related Outcomes in Patients with Aortic Neck Anatomy Outside of Instructions For Use (IFU) within the Global Registry for Endovascular Aortic Treatment (GREAT): Mid-term Follow-Up Results.0.4486160.0093776670research area of0.2254780.038720595subject area for36240471Alban J, DuVall A, Gurbuxani S, Stock W, Patel AAJCO precision oncologyOutcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.JCO Precis Oncol2022-10-01T00:00:002022Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.anand_88_patelMedicineUniversity of ChicagoWendyStockwHF9BKIeOfnamXNnYUHhvWD+6g==Wendy Stock41.78927490000000-87.601250000000001502Stock, WendyProfessorAndrzejJakubowiak1mhjCqp1G+POmHtvQFPt+2z5/syyp7BaZQ==Andrzej Jakubowiak41.78927490000000-87.601250000000002384Jakubowiak, AndrzejProfessorKennethGordonKenneth Gordon41.78927490000000-87.60125000000000340Gordon, KennethStephenHanauerStephen B. Hanauer41.78927490000000-87.60125000000000660Hanauer, StephenEmeritus/Emeritatrue1true1Emeritus/EmeritaEmeritus/Emeritatrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor